Lyall, D M
Harris, S E
Bastin, M E
Muñoz Maniega, S
Murray, C
Lutz, M W
Saunders, A M
Roses, A D
Valdés Hernández, M del C
Royle, N A
Starr, J M
Porteous, D J
Wardlaw, J M
Deary, I J
Article History
Received: 7 November 2013
Revised: 8 July 2014
Accepted: 7 August 2014
First Online: 23 September 2014
Competing interests
: ADR is the CEO and only stock holder of Zinfandel Pharmaceuticals, a company in an Alliance with Takeda Pharmaceuticals, to perform the prospective qualification of the <i>TOMM40</i> marker for age of onset distribution of Alzheimer’s disease. For this study, Zinfandel Pharmaceuticals paid for the <i>TOMM40</i> assays to be performed for medical research, not as a clinical diagnostic. AMS is the spouse of ADR, and AMS and MWL are consultants to Zinfandel Pharmaceuticals. The remaining authors declare no conflict of interest.